Aidence and Inobe, a leading MedTech distributor based in Warsaw, announce a partnership to pioneer artificial intelligence (AI) for early lung cancer detection and diagnosis in Poland. Inobe will market and support the deployment of Aidence’s AI solution, Veye Lung Nodules, in routine practice and lung cancer screening.
Inobe is building upon 15 years of experience in healthcare to deliver innovative solutions to the medical industry, with the main focus on radiology. Through the collaboration with Aidence, Inobe will introduce AI-based lung nodule assistant Veye Lung Nodules to radiology departments in hospitals across Poland.
Veye Lung Nodules is a clinically certified AI solution for detecting, classifying and tracking the growth of pulmonary nodules on chest CT scans. Currently used in Western Europe and the UK, Veye Lung Nodules analyses thousands of scans each week. In England, several sites involved in the Targeted Lung Health Checks (TLHC) pilots are using Veye Lung Nodules to help radiologists deal with the high additional workload required by the lung cancer screening protocols.
Lung cancer is the leading cause of cancer-related deaths in Poland. Early detection of the disease is crucial to offer patients better treatment options and chances of survival. In an effort to improve patient outcomes, Poland is currently implementing its first large-scale lung cancer screening programme. The pilot will cover six regions over the next three years.
Victor Groothengel, Aidence’s CCO, said:
“Our partnership with Inobe marks a major milestone: bringing our proven solution to Central and Eastern Europe. Having established a solid and growing network of users in the Netherlands, France and the UK, both in clinical routine and screening, the time has come to leverage these partnerships and bring our certified AI solution to Poland; to support precision diagnostics without compromising on costs.
Inobe’s rich healthcare-technology experience will help us tailor Veye Lung Nodules to the needs of Polish radiology and oncology teams. Together, we will ensure a reliable operation of AI in clinical practice, seamlessly integrated into the radiology workflow.”
Marcin Zalewski, CEO of Inobe, added:
“At Inobe, we focus on bringing innovation into healthcare. It means a lot to us that, as a company, we can introduce a pioneering AI solution to the market. We are therefore very excited to bring Veye Lung Nodules to the Polish market.
Technologies based on artificial intelligence are intensively developing, supporting radiologists at work by providing them with a ‘second pair of eyes’, which significantly contributes to reducing the time of diagnosis. We are entering a new era in which our traditional way of thinking will change.
It is our first project of this type, and not a small challenge, but I believe that, together with Aidence, we will be successful.”